Sector News

AstraZeneca loses second top executive as Vectura gets new CEO

June 24, 2015
Life sciences
(Reuters) – AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.
 
His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved on to become CEO of privately owned cancer drug firm Syndax.
 
An AstraZeneca spokeswoman said on Wednesday that the timing of the departures was “pure coincidence” and both men were moving on to new and different types of challenges as business leaders.
 
Vectura said Ward-Lilley would become CEO effective Oct. 1, replacing Chris Blackwell, whose departure had already been announced and who will leave the small drug company at the end of this month.
 
The move is a blow to AstraZeneca, which has identified respiratory medicine as one of its six growth businesses, alongside oncology, diabetes, the heart drug Brilinta, emerging markets and Japan.
 
AstraZeneca CEO Pascal Soriot, who took over in 2012 and successfully fought off a $118 billion takeover attempt by Pfizer last year, has sought to bolster the company’s respiratory franchise.
 
The drugmaker already boasts an established blockbuster in its inhaled treatment Symbicort, for asthma and chronic lung disease, and Soriot plans to build on that after buying Pearl Therapeutics in 2013 and Almirall’s lung drug business in 2014.
 
Vectura, whose shares traded 1 percent higher by mid-morning, said Trevor Phillips would act as interim CEO from the end of June until Ward-Lilley joined the company.
 
(Additional reporting by Roshni Menon in Bengaluru; Editing by Pravin Char)

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend